Table 2.
Previous studies of systemic chemotherapy that included more than five patients with PMP since 2000 and present study
| References | Farquharson et al. [9] | Pietrantonio et al. [10] | Pietrantonio et al. [11] | Present study |
|---|---|---|---|---|
| Study design | Single-center Phase II study | Single-center prospective observational study | Single-center prospective observational study | Single-center retrospective study |
| Regimen | Mitomycin C + capecitabine | FOLFOX4 | Capecitabine + bevacizumab | mFOLFOX6 |
| Number of patients | 40 | 20 | 15 | 8 |
| Pathology or pathological grade |
DPAM (n = 27)a PMCA (n = 3)a PMCA-I/D (n = 10)a |
High grade (n = 8)b Low grade (n = 12)b |
High grade (n = 5)b Low grade (n = 10)b |
High grade (n = 7)b Low grade (n = 1)b |
| ORR | Not applicable | 20% | 20% | not applicable |
| DCR | Not applicablec | 65% | 87% | 88% |
| Median PFS (months) | Not described | 8.0 | 8.2 | 13.0 |
| Median OS (months) | 2-year OS: 61% | 26.2 | 1-year OS: 91% | 27.9 |
ORR overall response rate, DCR disease control rate, PFS progression-free survival, OS overall survival, FOLFOX 5-fluorouracil and oxaliplatin, DPAM disseminated peritoneal adenomucinosis, PMCA peritoneal mucinous carcinomatosis, PMCA-I/D PMCA with intermediate or discordant features
aPathological classification described by Ronnett et al. was used [1]
bPathological classification described by Bradley et al. and the WHO Classification of Tumors of the Digestive System was used [2, 4]
cThe percentage of tumor reduction plus stabilization of progressive disease was 38% [9]